儿童非转移性尤文肉瘤41例分析

doi:10.7499/j.issn.1008-8830.2309077

摘要
图/表
参考文献(30)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (560 KB) [HTML]
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的总结儿童非转移性尤文肉瘤（Ewing sarcoma, ES）的临床特征、治疗结果和预后影响因素。方法对2010年1月—2018年12月上海交通大学医学院附属上海儿童医学中心诊治的41例非转移性ES初治患儿的临床资料进行回顾性分析。患儿均采用该中心横纹肌肉瘤?2009方案进行化疗，并根据危险度分组行手术和/或放疗等局部治疗。应用Kaplan?Meier方法计算总体生存率（overall survival, OS）、无事件生存率（event?free survival, EFS）。采用log?rank法行单因素预后分析，以Cox回归进行多因素分析。结果 41例患儿中，男21例，女20例；中位发病年龄为7.7岁（范围：1.2~14.6岁）；无事件生存患儿中位随访时间为68.1个月（范围：8.1~151.7个月）。截至末次随访，33例患儿无病生存，41例患儿总体5年EFS为（78±6）%，5年OS为（82±6）%。log?rank检验单因素分析显示，肿块直径≥8 cm、诊断至局部治疗开始时间≥16周及手术未完整切除者预后差（均P<0.05）。Cox多因素分析显示，手术未完整切除（HR=8.381，95%CI：1.681~41.801，P=0.010）是ES患儿预后差的独立危险因素。2例发生了第二肿瘤。结论 ES患儿采用化疗、手术及放疗的综合治疗预后较好；初诊时肿块直径≥8 cm者的预后较差，而手术完整切除和早期开始局部治疗可改善预后。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	袁晴
	韩亚丽
	潘慈
	汤静燕
	高怡瑾

关键词 ：尤文肉瘤, 预后, 危险因素, 儿童

Abstract：Objective To summarize the clinical characteristics, treatment outcomes, and prognostic factors of children with non-metastatic Ewing's sarcoma (ES). Methods A retrospective analysis was conducted on the clinical data of 41 children with non-metastatic ES diagnosed and treated at the Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine from January 2010 to December 2018. All patients underwent chemotherapy based on the RMS-2009 protocol of the center, and local treatment such as surgery and/or radiotherapy was performed according to risk grouping. The Kaplan-Meier method was used to calculate the overall survival (OS) and event-free survival (EFS) rates. Univariate prognostic analysis was performed using the log-rank test, and multivariate analysis was conducted with Cox regression. Results Of the 41 children, 21 were male and 20 were female. The median age at diagnosis was 7.7 years (range: 1.2-14.6 years). The median follow-up time for patients with event-free survival was 68.1 months (range: 8.1-151.7 months). As of the last follow-up, 33 patients were in complete remission, and the overall 5-year EFS and OS rates were (78±6)% and (82±6)%, respectively. Univariate analysis by the log-rank test showed that a tumor diameter ≥8 cm, time from diagnosis to start of local treatment ≥16 weeks, and incomplete surgical resection were associated with poor prognosis (P<0.05). Multivariate Cox regression analysis indicated that incomplete surgical resection (HR=8.381, 95%CI: 1.681-41.801, P=0.010) was an independent risk factor for poor prognosis in children with ES. Secondary tumors occurred in 2 cases. Conclusions A comprehensive treatment strategy incorporating chemotherapy, surgery, and radiotherapy can improve the prognosis of children with ES. Poor prognosis is associated with an initial tumor diameter ≥8 cm, while complete surgical resection and early initiation of local treatment can improve outcomes.

Key words： Ewing's sarcoma Prognosis Risk Factor Child

收稿日期: 2023-09-15

通讯作者: 高怡瑾，女，主任医师，教授。Email：gaoyijin@scmc.com.cn。 E-mail: gaoyijin@scmc.com.cn

作者简介: 袁晴，女，硕士，住院医师；

引用本文:

袁晴,韩亚丽,潘慈等. 儿童非转移性尤文肉瘤41例分析[J]. 中国当代儿科杂志, 2024, 26(4): 365-370.

YUAN Qing,HAN Ya-Li,PAN Ci et al. Analysis of 41 cases of non-metastatic Ewing's sarcoma in children[J]. CJCP, 2024, 26(4): 365-370.

链接本文:

http://www.zgddek.com/CN/10.7499/j.issn.1008-8830.2309077 或 http://www.zgddek.com/CN/Y2024/V26/I4/365

	Eaton BR, Claude L, Indelicato DJ, et al. Ewing sarcoma[J]. Pediatr Blood Cancer, 2021, 68 (Suppl 2): e28355. PMID: 33818887. DOI: 10.1002/pbc.28355.
	Gargallo P, Yá?ez Y, Juan A, et al. Review: Ewing sarcoma predisposition[J]. Pathol Oncol Res, 2020, 26(4): 2057-2066. PMID: 31656020. DOI: 10.1007/s12253-019-00765-3.
	Grünewald TGP, Cidre-Aranaz F, Surdez D, et al. Ewing sarcoma[J]. Nat Rev Dis Primers, 2018, 4(1): 5. PMID: 29977059. DOI: 10.1038/s41572-018-0003-x.
	Riggi N, Suvà ML, Stamenkovic I. Ewing's sarcoma[J]. Engl J Med, 2021, 384(2): 154-164. PMID: 33497548. DOI: 10.1056/NEJMra2028910.
	Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group[J]. J Clin Oncol, 2012, 30(33): 4148-4154. PMID: 23091096. PMCID: PMC3494838. DOI: 10.1200/JCO.2011.41.5703.
	Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment[J]. Cancer, 1981, 47(1): 207-214. PMID: 7459811. DOI: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6.
	Chin M, Yokoyama R, Sumi M, et al. Multimodal treatment including standard chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for the Ewing sarcoma family of tumors in Japan: results of the Japan Ewing Sarcoma Study 04[J]. Pediatr Blood Cancer, 2020, 67(5): e28194. PMID: 32077253. DOI: 10.1002/pbc.28194.
	Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study[J]. J Clin Oncol, 2009, 27(15): 2536-2541. PMID: 19349548. PMCID: PMC2684856. DOI: 10.1200/JCO.2008.19.1478.
	Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone[J]. N Engl J Med, 2003, 348(8): 694-701. PMID: 12594313. DOI: 10.1056/NEJMoa020890.
	Juergens C, Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial[J]. Pediatr Blood Cancer, 2006, 47(1): 22-29. PMID: 16572419. DOI: 10.1002/pbc.20820.
	Whelan J, Le Deley MC, Dirksen U, et al. High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk Ewing sarcoma: results of Euro-E.W.I.N.G.99 and Ewing-2008[J]. J Clin Oncol, 2018, 36(31): JCO2018782516. PMID: 30188789. PMCID: PMC6209090. DOI: 10.1200/JCO.2018.78.2516.
	12 董玉双, 谈珍, 张勤, 等. 儿童尤文肉瘤家族肿瘤50例临床病理特点及预后因素分析[J]. 临床儿科杂志, 2020, 38(7): 530-535. DOI: 10.3969/j.issn.1000-3606.2020.07.012.
	Kapoor G, Jain S. Choice of local therapy in children with Ewing sarcoma[J]. Indian Pediatr, 2020, 57(6): 503-504. PMID: 32562393.
	Lin TA, Ludmir EB, Liao KP, et al. Timing of local therapy affects survival in Ewing sarcoma[J]. Int J Radiat Oncol Biol Phys, 2019, 104(1): 127-136. PMID: 30593906. DOI: 10.1016/j.ijrobp.2018.12.032.
	Salah S, Halalsheh H, Abuhijla F, et al. The impact of local control timing in Ewing sarcoma[J]. Rep Pract Oncol Radiother, 2020, 25(2): 255-259. PMID: 32140082. PMCID: PMC7049602. DOI: 10.1016/j.rpor.2020.02.001.
	Schuck A, Ahrens S, Paulussen M, et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials[J]. Int J Radiat Oncol Biol Phys, 2003, 55(1): 168-177. PMID: 12504050. DOI: 10.1016/s0360-3016(02)03797-5.
	Whelan J, Hackshaw A, McTiernan A, et al. Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92[J]. Clin Sarcoma Res, 2018, 8: 6. PMID: 29610659. PMCID: PMC5877389. DOI: 10.1186/s13569-018-0093-y.
	Yock TI, Krailo M, Fryer CJ, et al. Local control in pelvic Ewing sarcoma: analysis from INT-0091—a report from the Children's Oncology Group[J]. J Clin Oncol, 2006, 24(24): 3838-3843. PMID: 16921035. DOI: 10.1200/JCO.2006.05.9188.
	Z?llner SK, Amatruda JF, Bauer S, et al. Ewing sarcoma-diagnosis, treatment, clinical challenges and future perspectives[J]. J Clin Med, 2021, 10(8): 1685. PMID: 33919988. PMCID: PMC8071040. DOI: 10.3390/jcm10081685.
	Abbott D, O'Brien S, Farnham JM, et al. Increased risk for other cancers in individuals with Ewing sarcoma and their relatives[J]. Cancer Med, 2019, 8(18): 7924-7930. PMID: 31670911. PMCID: PMC6912049. DOI: 10.1002/cam4.2575.
	Caruso J, Shulman DS, DuBois SG. Second malignancies in patients treated for Ewing sarcoma: a systematic review[J]. Pediatr Blood Cancer, 2019, 66(11): e27938. PMID: 31347793. DOI: 10.1002/pbc.27938.
	Friedman DN, Chastain K, Chou JF, et al. Morbidity and mortality after treatment of Ewing sarcoma: a single-institution experience[J]. Pediatr Blood Cancer, 2017, 64(11): e26562. PMID: 28417551. DOI: 10.1002/pbc.26562.
	Nguyen F, Rubino C, Guerin S, et al. Risk of a second malignant neoplasm after cancer in childhood treated with radiotherapy: correlation with the integral dose restricted to the irradiated fields[J]. Int J Radiat Oncol Biol Phys, 2008, 70(3): 908-915. PMID: 18262102. DOI: 10.1016/j.ijrobp.2007.10.034.
	Sanford NN, Miao R, Wang H, et al. Characteristics and predictors for secondary leukemia and myelodysplastic syndrome in Ewing and osteosarcoma survivors[J]. Int J Radiat Oncol Biol Phys, 2019, 103(1): 52-61. PMID: 30165126. DOI: 10.1016/j.ijrobp.2018.08.037.
	Hong KT, Choi JY, Hong CR, et al. Therapy-related acute myeloid leukemia after the treatment of primary solid cancer in children: a single-center experience[J]. J Pediatr Hematol Oncol, 2018, 40(1): e23-e28. PMID: 29200163. DOI: 10.1097/MPH.0000000000001019.
	Sultan I, Rihani R, Hazin R, et al. Second malignancies in patients with Ewing sarcoma family of tumors: a population-based study[J]. Acta Oncol, 2010, 49(2): 237-244. PMID: 20100158. DOI: 10.3109/02841860903253538.
	Vyas C, Jain S, Kapoor G. Therapy related AML/MDS following treatment for childhood cancer: experience from a tertiary care centre in north India[J]. Indian J Hematol Blood Transfus, 2018, 34(1): 78-82. PMID: 29398803. PMCID: PMC5786633. DOI: 10.1007/s12288-017-0840-x.
	Zhang J, Nichols KE, Downing JR. Germline mutations in predisposition genes in pediatric cancer[J]. N Engl J Med, 2016, 374(14): 1391. PMID: 27050224. DOI: 10.1056/NEJMc1600338.
	Renzi S, Anderson ND, Light N, et al. Ewing-like sarcoma: an emerging family of round cell sarcomas[J]. J Cell Physiol, 2019, 234(6): 7999-8007. PMID: 30257034. DOI: 10.1002/jcp.27558.
	Sbaraglia M, Righi A, Gambarotti M, et al. Ewing sarcoma and Ewing-like tumors[J]. Virchows Arch, 2020, 476(1): 109-119. PMID: 31802230. DOI: 10.1007/s00428-019-02720-8.